Quotient Limited Stock News

JERSEY, Channel Islands, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its third quarter fiscal 2022 key financial results and furnished an update on recent business developments.

Quotient (QTNT) delivered earnings and revenue surprises of -76% and 10.57%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Companies Reporting Before The Bell Pfizer (NYSE: PFE ) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion. Karyopharm Therapeutics (NASDAQ: KPTI ) is likely to report quarterly loss at $0.49 per share on revenue of $50.49 million. Thomson Reuters (NYSE: TRI ) is estimated to report quarterly earnings at $0.46 per share on revenue of $1.68 billion. Beasley Broadcast Group (NASDAQ: BBGI ) is likely to report quarterly earnings at $0.03 per share on revenue of $69.67 million. Willis Towers Watson (NASDAQ: WTW ) is projected to report quarterly earnings at $4.98 per share on revenue of $2.50 billion. Cenovus Energy (NYSE: CVE ) is expected to report quarterly earnings at $0.39 per share on revenue of $11.25 billion. Jacobs Engineering Group (NYSE: J ) is projected to report quarterly earnings at $1.58 per share on revenue of $3.51 billion. CTS (NYSE: CTS ) is estimated to report quarterly earnings at $0.47 per share on revenue of $122.96 million.

Nuformix PLC (LSE:NFX) said Oxilio has signed a service contract to support the formulation development of NXP-001, which the latter has licensed from the former. Oxilio in turn is working with Quotie

Quotient (NASDAQ:QTNT) is scheduled to announce FQ3 earnings results on Tuesday, February 8th, before market open.The consensus EPS Estimate is -$0.27 (+6.9% Y/Y) and the consensus…

JERSEY, Channel Islands, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2021 will be released before market open on Tuesday, February 8, 2022.

JERSEY, Channel Islands, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter

Quotient (QTNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quotient (QTNT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Quotient (NASDAQ:QTNT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Friday, Zacks.com reports. The firm currently has a $2.50 price target on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 0.40% from the stock’s current price. According […]

Zacks Investment Research downgraded shares of Quotient (NASDAQ:QTNT) from a buy rating to a hold rating in a report issued on Wednesday, Zacks.com reports. According to Zacks, Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and []

FRND has raised $6.5 million in Series A funding round led by BGMI creator KRAFTON Inc and existing investors India Quotient and Elevation Capital

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

SALT LAKE CITY--(BUSINESS WIRE)---- $QUOT--Quotient''s innovative, omnichannel Social Platform has won a Digiday 2021 Technology Award in the Best Influencer Marketing Platform category.

JERSEY, Channel Islands, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced the company received feedback from the European notified body on the Expanded Immunohematology (IH) submission. The Company is pleased with the feedback and expects to submit a response to the questions in the next couple of weeks.